Dasatinibobservational2022

A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues.

Nature communications

confidence

Key findings

SenMayo gene set identifies senescent cells across tissues and species; not a clinical endpoint study for dasatinib.

View source on PubMed (PMID 35974106) ↗

Sample size
Not reported
Population
Human and murine bone marrow/bone scRNA-seq data; aged human bone biopsies; mice with genetic senescent cell clearance; humans with pharmacological senescent cell clearance
Dosing
Not reported
Duration
Not reported
Route
Not reported
Blinding
not_reported
Controls
none
Drug class
senolytic
Full abstract

Although cellular senescence drives multiple age-related co-morbidities through the senescence-associated secretory phenotype, in vivo senescent cell identification remains challenging. Here, we generate a gene set (SenMayo) and validate its enrichment in bone biopsies from two aged human cohorts. We further demonstrate reductions in SenMayo in bone following genetic clearance of senescent cells in mice and in adipose tissue from humans following pharmacological senescent cell clearance. We next use SenMayo to identify senescent hematopoietic or mesenchymal cells at the single cell level from human and murine bone marrow/bone scRNA-seq data. Thus, SenMayo identifies senescent cells across tissues and species with high fidelity. Using this senescence panel, we are able to characterize senescent cells at the single cell level and identify key intercellular signaling pathways. SenMayo also represents a potentially clinically applicable panel for monitoring senescent cell burden with aging and other conditions as well as in studies of senolytic drugs.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.